When does this change take effect?

This change is effective Dec 10, 2025.

Medicare AdvantageCoverageMedium impact

MA08.149a, Inclisiran (Leqvio®)

Q: Who is affected by this change?

This affects Independence Blue Cross Cardiology, Endocrinology, Internal Medicine, Family Medicine providers on Medicare Advantage plans.

Independence Blue Cross·Cardiology, Endocrinology, Internal Medicine +1 more·Pharmacy

Effective date

Dec 10, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.149a for Inclisiran (Leqvio®) has been reissued with updates effective December 10, 2025. This pharmacy policy change affects coverage and billing requirements for this cholesterol-lowering medication.

Action Required

Action needed

By December 10, 2025: Billing team must review updated MA08.149a policy for Inclisiran (Leqvio®) at the provided URL to identify specific changes to prior authorization, coverage criteria, or billing requirements. Update billing system and provider workflows accordingly based on the detailed policy content.

Related policy hubs

Independence Blue Cross policies Cardiology Endocrinology Internal Medicine Family Medicine